News | March 19, 2015

Study Shows ST2 Biomarker Predicts Outcomes for Hospitalized Heart Failure Patients

Patients whose ST2 levels failed to drop within 48 to 72 hours were nearly three times as likely to die

ST2, cardiac biomarker, Critical Diagnostics, heart failure, predict outcomes

March 19, 2015 — According to an abstract presented at the American College of Cardiology (ACC) Scientific Sessions in San Diego, elevated levels of the cardiac biomarker ST2 were associated with an increased risk of adverse events in hospitalized heart failure patients.

Authors of the abstract (“Prognostic Value of Baseline and Changes in Circulating Soluble ST2 Levels and the Effects of Nesiritide in Acute Decompensated Heart Failure”) include W.H. Wilson Tang of Cleveland Clinic, and Michael Felker and Christopher O’Connor of Duke University Medical Center and Duke Clinical Research Institute. Critical Diagnostics reported on the presentation.

Part of a large multinational, multi-center, prospective randomized study (ASCEND-HF) of hospitalized patients with acute decompensated heart failure, this 858-patient cohort showed higher levels of ST2 were associated with increased risk of death. Moreover, patients whose ST2 levels failed to drop within 48 to 72 hours were more than two-and-a-half times as likely to die, compared to those whose ST2 levels dropped.

About 1.1 million heart failure patients will be discharged from hospital in the United States this year. In fact, heart failure is the leading cause of hospitalization in people over 65 years of age. However, almost one quarter of these discharged heart failure patients will be rehospitalized within 30 days of discharge, with an average cost per patient for rehospitalization of $22,700. Front and center are Centers for Medicare and Medicaid’s regulations on preventable readmissions. They state that hospitals with rates of rehospitalization significantly higher than expected lose 3 percent of their Medicare reimbursement across the board — not just for heart failure.

When implemented correctly, though, intensive disease management programs have been demonstrated to reduce 30-day rehospitalization and mortality rates, but correct identification of those most likely to benefit from such intervention is challenging. Consequently, broadly implemented disease management programs have not provided a cost effective reduction in rehospitalization rates. Since hospitals don’t have the ability to monitor all discharged patients, using ST2 allows for the risk stratification of these patients, thus enabling more focused management for those that need it most, while keeping costs in check.

A 2013 study from Basel Switzerland and Brigham and Women's Hospital and Harvard Medical School demonstrated ST2 values accurately predict heart failure event risk in hospitalized heart failure patients. Levels of ST2 were measured at presentation to the emergency department and after 48 hours in 207 patients with acute heart failure. In univariate analysis the percentage change of ST2 over the first 48 hours significantly predicted long-term mortality.

In multivariable analysis, the predictive potential of early ST2 changes persisted after the adjustment for ADHERE risk factors (blood urea nitrogen, systolic blood-pressure and serum creatinine), traditional markers of inflammation (total white cell count and high- sensitive C-reactive protein), BNP, troponin T and percentage BNP changes during the first 48 hours as well as the cumulative diuretic dose administered during the first 48 hours.

Shannon M. Dunlay, M.D., and Allan S. Jaffe, M.D., of Mayo Clinic, published a paper in 2013 in Clinical Chemistry titled, “Are Biomarkers the Answer to the Heart Failure Readmissions Problem?” In it, ST2 was declared to be “the most potent predictor of rehospitalization of all biomarkers assessed.” And, notably, it demonstrated that serial changes in ST2 were superior to both BNP and troponin — the two most-often used cardiac biomarkers — in the prediction of adverse events in otherwise stable chronic heart failure patients.

As the paper pointed out, the use of BNP was “no better than a flip of a coin” in predicting hospital readmissions, and therefore was no help in addressing this healthcare dilemma. Furthermore, the wide biological variation of BNP — which is affected by such confounding factors as age, body mass index, renal failure, smoking and other comorbidities common to heart failure patients — means “marked changes are necessary with BNP measures to be sure they are not simply due to spontaneous variation.” ST2 is not affected by these confounding factors.

In another paper published last year by Lori Daniels, M.D., and Tony Bayes-Genis, M.D., titled, “Using ST2 in Cardiovascular Patients: A Review” in Future Cardiology, a specific recommendation made is that “serial ST2 levels can be used to identify ‘ST2 nonresponders,’ or individuals whose ST2 levels fail to drop at least 15–25 percent within 2 weeks after an acute heart failure exacerbation. Such individuals are at increased risk for adverse outcomes.”

For more information: www.criticaldiagnostics.com

Related Content

BioCardia Announces 12-Month Results from TRIDENT Trial of Stem Cell Delivery System
News | Stem Cell Therapies| September 26, 2017
BioCardia Inc. recently announced 12-month results from the Phase II TRIDENT clinical trial, conducted by the...
News | Vena Cava Filters| September 26, 2017
September 26, 2017 — The one-year results of the SENTRY...
Treatment of Heart Attack Patients Depends on Cancer History
News | Cardio-oncology| September 26, 2017
Treatment of heart attack patients depends on their history of cancer, according to research published recently in...
CardiAMP Heart Failure Trial Design Presented at Texas Heart Institute Symposium
News | Heart Failure| September 25, 2017
BioCardia Inc. announced the trial design for its pivotal Phase III CardiAMP Heart Failure Trial was presented during...
Biotronik Studies Demonstrate Efficacy of Minimizing Metal Burden in SFA Therapy
News | Stents Bare Metal| September 22, 2017
Physicians demonstrated that reducing metal burden in superficial femoral artery (SFA) therapy could effectively reduce...
Edwards Inspiris Resilia Valve Receives FDA Approval
News | Heart Valve Technology| September 21, 2017
Edwards Lifesciences Corp. recently received U.S. Food and Drug Administration (FDA) approval for its Inspiris Resilia...
MyoKardia Presents Additional Positive Data From Phase 2 PIONEER-HCM Study at HFSA 2017
News | Heart Failure| September 21, 2017
MyoKardia Inc. announced that additional positive data from the first patient cohort of its Phase 2 PIONEER-HCM study...
DISRUPT BTK Study Shows Positive Results With Lithoplasty in Calcified Lesions Below the Knee
News | Peripheral Artery Disease (PAD)| September 20, 2017
Shockwave Medical reported positive results from the DISRUPT BTK Study, which were presented at the annual...
Heart Failure Market to Surpass $16 Billion by 2026
News | Heart Failure| September 19, 2017
The heart failure space across the seven key markets of the U.S., France, Germany, Italy, Spain, the U.K. and Japan is...
Corindus Announces First Patient Enrolled in PRECISION GRX Registry
News | Robotic Systems| September 18, 2017
September 18, 2017 — Corindus Vascular Robotics Inc.
Overlay Init